Genomics and epigenomics in novel schizophrenia drug discovery: translating animal models to clinical research and back

Bibliography

• World Health Organization. International classification of diseases. 10th edition. WHO; Geneva: 1990
   Google Scholar
• Murray CL and Lopez AD. The global burden of disease. Harvard University Press; Cambridge: 1996
   Google Scholar
• Dold M, Leucht S. Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective. Evid Based Ment Health 2014;17(2):33-7
   PubMedGoogle Scholar
• Remington G, Saha A, Chong SA, Shammi C. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 2005;19(10):843-72
   PubMed Web of Science ®Google Scholar
• Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics : differential risk and clinical implications. CNS Drugs 2007;21(11):911-36
   PubMed Web of Science ®Google Scholar
• Kirkby KC. Social context and health consequences of the antipsychotics introduction. Ann Clin Psychiatry 2005;17(3):141-6
   PubMedGoogle Scholar
• Lieberman JA. Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia. J Clin Psychiatry 1999;60(Suppl 12):9-12
   PubMedGoogle Scholar
• Keefe RS. The longitudinal course of cognitive impairment in schizophrenia: an examination of data from premorbid through posttreatment phases of illness. J Clin Psychiatry 2014;75(Suppl 2):8-13
   PubMed Web of Science ®Google Scholar
• Kane JM. Extrapyramidal side effects are unacceptable. Eur Neuropsychopharmacol 2001;11(Suppl 4):S397-403
   PubMed Web of Science ®Google Scholar
• Casey DE. Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia. J Clin Psychiatry 1998;59(Suppl 3):31-7
   PubMed Web of Science ®Google Scholar
• Barbui C, Conti V, Purgato M, et al. Use of antipsychotic drugs and mood stabilizers in women of childbearing age with schizophrenia and bipolar disorder: epidemiological survey. Epidemiol Psychiatr Sci 2013;22(4):355-61
   Web of Science ®Google Scholar
• Gouveia C, Chowdhury TA. Diabetes. Schizophrenia and metabolic effects of antipsychotic drugs. Ment Health Today 2013;24-7
   PubMedGoogle Scholar
• Gupta A, Dadheech G, Yadav D, et al. Metabolic issues in schizophrenic patients receiving antipsychotic treatment.Indian J Clin Biochem. 2014;29(2):196-201
   Google Scholar
• Chung AK, Chua SE. Effects on prolongation of Bazett’s corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: a meta-analysis. J Psychopharmacol 2011;25(5):646-66
   PubMed Web of Science ®Google Scholar
• Raja M, Raja S. Clozapine safety, 40 years later. Curr Drug Saf 2014. [ Epub ahead of print]
   PubMedGoogle Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness (CATIE) Investigators. Clinical antipsychotic trials of intervention effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-23
   PubMed Web of Science ®Google Scholar
• Fakra E, Azorin JM. Clozapine for the treatment of schizophrenia. Expert Opin Pharmacother 2012;13(13):1923-35
   PubMed Web of Science ®Google Scholar
• Zhang JP, Gallego JA, Robinson DG, et al. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol 2013;16(6):1205-18
   PubMed Web of Science ®Google Scholar
• Purkayastha S, Ford J, Kanjilal B, et al. Clozapine functions through the prefrontal cortex serotonin 1A receptor to heighten neuronal activity via calmodulin kinase II-NMDA receptor interactions. J Neurochem 2012;120(3):396-407
   PubMed Web of Science ®Google Scholar
• Angelucci F, Mathé AA, Aloe L. Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration. J Neurosci Res 2000;60(6):783-94
   PubMed Web of Science ®Google Scholar
• Bai O, Chlan-Fourney J, Bowen R, et al. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res 2003;71(1):127-31
   PubMed Web of Science ®Google Scholar
• Insel TR. Rethinking schizophrenia. Nature 2010;468(7321):187-93
   PubMed Web of Science ®Google Scholar
• Brzustowicz LM, Bassett AS. Phenotype matters: the case for careful characterization of relevant traits. Am J Psychiatry 2008;165(9):1096-8
   PubMed Web of Science ®Google Scholar
• Rapoport JL, Addington AM, Frangou S, Psych MR. The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 2005;10(5):434-49
   PubMed Web of Science ®Google Scholar
• Arnsten AF. Prefrontal cortical network connections: key site of vulnerability in stress and schizophrenia. Int J Dev Neurosci 2011;29(3):215-23
   PubMed Web of Science ®Google Scholar
• Gottesman LE, Peskin E, Kennedy K, Mossey J. Implications of a mental health intervention for elderly mentally ill residents of residential care facilities. Int J Aging Hum Dev 1991;32(3):229-45
   PubMed Web of Science ®Google Scholar
• Burmeister M, McInnis MG, Zöllner S. Psychiatric genetics: progress amid controversy. Nat Rev Genet 2008;9(7):527-40
   PubMed Web of Science ®Google Scholar
• O’Donovan MC, Craddock NJ, Owen MJ. Genetics of psychosis; insights from views across the genome. Hum Genet 2009;126(1):3-12
   PubMed Web of Science ®Google Scholar
• Chen Y, Hancock ML, Role LW, Talmage DA. Intramembranous valine linked to schizophrenia is required for neuregulin 1 regulation of the morphological development of cortical neurons. J Neurosci 2010;30:9199-208
   PubMed Web of Science ®Google Scholar
• Zuo L, Luo X, Kranzler HR, et al. Association study of DTNBP1 with schizophrenia in a US sample. Psychiatr Genet 2009;19(6):292-304
   PubMed Web of Science ®Google Scholar
• Lipska BK, Peters T, Hyde TM, et al. Expression of DISC1 binding partners is reduced in schizophrenia and associated with DISC1 SNPs. Hum Mol Genet 2006;15(8):1245-58
   PubMed Web of Science ®Google Scholar
• Opgen-Rhein C, Lencz T, Burdick KE, et al. Genetic variation in the DAOA gene complex: impact on susceptibility for schizophrenia and on cognitive performance. Schizophr Res 2008;103(1-3):169-77
   PubMed Web of Science ®Google Scholar
• O’Donovan MC, Craddock N, Norton N, et al. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet 2008;40(9):1053-5
   PubMed Web of Science ®Google Scholar
• Wilson GM, Flibotte S, Chopra V, et al. DNA copy-number analysis in bipolar disorder and schizophrenia reveals aberrations in genes involved in glutamate signaling. Hum Mol Genet 2006;15(5):743-9
   PubMed Web of Science ®Google Scholar
• Del Pino I, García-Frigola C, Dehorter N, et al. Erbb4 deletion from fast-spiking interneurons causes schizophrenia-like phenotypes. Neuron 2013;79(6):1152-68
   PubMed Web of Science ®Google Scholar
• Yamamori H, Hashimoto R, Verrall L, et al. Dysbindin-1 and NRG-1 gene expression in immortalized lymphocytes from patients with schizophrenia. J Hum Genet 2011;56(7):478-83
   PubMed Web of Science ®Google Scholar
• Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014;511(7510):421-7
   PubMed Web of Science ®Google Scholar
• Sullivan PF. The psychiatric GWAS consortium: big science comes to psychiatry. Neuron 2010;68(2):182-6
   PubMed Web of Science ®Google Scholar
• Stefansson H, Ophoff RA, Steinberg S, et al. Common variants conferring risk of schizophrenia. Nature 2009;460(7256):744-7
   PubMed Web of Science ®Google Scholar
• Ivorra JL, Rivero O, Costas J, et al. Replication of previous genome-wide association studies of psychiatric diseases in a large schizophrenia case-control sample from Spain. Schizophr Res 2014;159(1):107-13
   PubMed Web of Science ®Google Scholar
• Kwon E, Wang W, Tsai LH. Validation of schizophrenia-associated genes CSMD1, C10orf26, CACNA1C and TCF4 as miR-137 targets. Mol Psychiatry 2013;18(1):11-12
   PubMed Web of Science ®Google Scholar
• Bassett AS, Scherer SW, Brzustowicz LM. Copy number variations in schizophrenia: critical review and new perspectives on concepts of genetics and disease. Am J Psychiatry 2010;167(8):899-914
   PubMed Web of Science ®Google Scholar
• Costain G, Bassett AS. Clinical applications of schizophrenia genetics: genetic diagnosis, risk, and counseling in the molecular era. Appl Clin Genet 2012;5:1-18
   Google Scholar
• Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003;160(4):636-45
   PubMed Web of Science ®Google Scholar
• Erk S, Meyer-Lindenberg A, Schmierer P, et al. Hippocampal and frontolimbic function as intermediate phenotype for psychosis: evidence from healthy relatives and a common risk variant in CACNA1C. Biol Psychiatry 2013;76(6):466-75
   PubMed Web of Science ®Google Scholar
• Marder SR. Perspective: retreat from the radical Nature. 2014;508(7494):S18
   Google Scholar
• Williams M. Commentary: genome-based CNS drug discovery: d-amino acid oxidase (DAAO) as a novel target for antipsychotic medications: progress and challenges. Biochem Pharmacol 2009;78:1360-5
   PubMed Web of Science ®Google Scholar
• Hall J, Whalley HC, Moorhead TW, et al. Genetic variation in the DAOA (G72) gene modulates hippocampal function in subjects at high risk of schizophrenia. Biol Psychiatry 2008;64(5):428-33
   PubMed Web of Science ®Google Scholar
• Adage T, Trillat AC, Quattropani A, et al. In vitro and in vivo pharmacological profile of AS057278, a selective d-amino acid oxidase inhibitor with potential anti-psychotic properties. Eur Neuropsychopharmacol 2008;18(3):200-14
   PubMed Web of Science ®Google Scholar
• Dong E, Guidotti A, Grayson DR, Costa E. Histone hyperacetylation induces demethylation of reelin and 67-kDa glutamic acid decarboxylase promoters. Proc Natl Acad Sci U S A 2007;104(11):4676-81
   PubMed Web of Science ®Google Scholar
• Ogawa S, Okuyama S, Araki H, et al. A rat model of phencyclidine psychosis. Life Sci 1994;55(21):1605-10
   PubMed Web of Science ®Google Scholar
• Ayhan Y, Abazyan B, Nomura J, et al. Differential effects of prenatal and postnatal expressions of mutant human DISC1 on neurobehavioral phenotypes in transgenic mice: evidence for neurodevelopmental origin of major psychiatric disorders. Mol Psychiatry 2011;16(3):293-306
   PubMed Web of Science ®Google Scholar
• Dempster EL, Pidsley R, Schalkwyk LC, et al. Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder. Hum Mol Genet 2011;20(24):4786-96
   PubMed Web of Science ®Google Scholar
• Benedetti F, Radaelli D, Poletti S, et al. Emotional reactivity in chronic schizophrenia: structural and functional brain correlates and the influence of adverse childhood experiences. Psychol Med 2011;41(3):509-19
   PubMed Web of Science ®Google Scholar
• van der Knaap LJ, Schaefer JM, Franken IH, et al. Catechol-O-methyltransferase gene methylation and substance use in adolescents: the TRAILS study. Genes Brain Behav 2014;13(7):618-25
   PubMed Web of Science ®Google Scholar
• Dempster E, Viana J, Pidsley R, Mill J. Epigenetic studies of schizophrenia: progress, predicaments, and promises for the future. Schizophr Bull 2013;39(1):11-16
   PubMed Web of Science ®Google Scholar
• Aberg KA, McClay JL, Nerella S, et al. Methylome-wide association study of schizophrenia: identifying blood biomarker signatures of environmental insults. JAMA Psychiatry 2014;71(3):255-64
   PubMed Web of Science ®Google Scholar
• Chase KA, Gavin DP, Guidotti A, Sharma RP. Histone methylation at H3K9: evidence for a restrictive epigenome in schizophrenia. Schizophr Res 2013;149(1-3):15-20
   PubMed Web of Science ®Google Scholar
• Abdolmaleky HM, Cheng KH, Faraone SV, et al. Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum Mol Genet 2006;15:3132-45
   PubMed Web of Science ®Google Scholar
• Abdolmaleky HM, Yaqubi S, Papageorgis P, et al. Epigenetic dysregulation of HTR2A in the brain of patients with schizophrenia and bipolar disorder. Schizophr Res 2011;129:183-90
   PubMed Web of Science ®Google Scholar
• Carrard A, Salzmann A, Malafosse A, Karege F. Increased DNA methylation status of the serotonin receptor 5HTR1A gene promoter in schizophrenia and bipolar disorder. J Affect Disord 2011;132:450-3
   PubMed Web of Science ®Google Scholar
• Dempster EL, Mill J, Craig IW, Collier DA. The quantification of COMT mRNA in post mortem cerebellum tissue: diagnosis, genotype, methylation and expression. BMC Med Genet 2006;7:10
   PubMed Web of Science ®Google Scholar
• Ghadirivasfi M, Nohesara S, Ahmadkhaniha HR, et al. Hypomethylation of the serotonin receptor type-2A Gene (HTR2A) at T102C polymorphic site in DNA derived from the saliva of patients with schizophrenia and bipolar disorder. Am J Med Genet B Neuropsychiatr Genet 2011;156B:536-45
   PubMed Web of Science ®Google Scholar
• Grayson DR, Jia X, Chen Y, et al. Reelin promoter hypermethylation in schizophrenia. Proc Natl Acad Sci U S A 2005;102:9341-6
   PubMed Web of Science ®Google Scholar
• Melas PA, Rogdaki M, Ösby U, et al. Epigenetic aberrations in leukocytes of patients with schizophrenia: association of global DNA methylation with antipsychotic drug treatment and disease onset. FASEB J 2012;26:2712-18
   PubMed Web of Science ®Google Scholar
• Nohesara S, Ghadirivasfi M, Mostafavi S, et al. DNA hypomethylation of MB-COMT promoter in the DNA derived from saliva in schizophrenia and bipolar disorder. J Psychiatr Res 2011;45:1432-8
   PubMed Web of Science ®Google Scholar
• Tolosa A, Sanjuán J, Dagnall AM, et al. FOXP2 gene and language impairment in schizophrenia: association and epigenetic studies. BMC Med Genet 2010;11:114
   Google Scholar
• Tochigi M, Iwamoto K, Bundo M, et al. Methylation status of the reelin promoter region in the brain of schizophrenic patients. Biol Psychiatry 2008;63:530-3
   Google Scholar
• Shimabukuro M, Sasaki T, Imamura A, et al. Global hypomethylation of peripheral leukocyte DNA in male patients with schizophrenia: a potential link between epigenetics and schizophrenia. J Psychiatr Res 2007;41(12):1042-6
   PubMed Web of Science ®Google Scholar
• Ikegame T, Bundo M, Sunaga F, et al. DNA methylation analysis of BDNF gene promoters in peripheral blood cells of schizophrenia patients. Neurosci Res 2013;77(4):208-14
   PubMed Web of Science ®Google Scholar
• Wockner LF, Noble EP, Lawford BR, et al. Genome-wide DNA methylation analysis of human brain tissue from schizophrenia patients. Transl Psychiatry 2014;4:e339
   PubMed Web of Science ®Google Scholar
• Mill J, Tang T, Kaminsky Z, et al. Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am J Hum Genet 2008;82:696-711
   PubMed Web of Science ®Google Scholar
• Huang HS, Akbarian S. GAD1 mRNA expression and DNA methylation in prefrontal cortex of subjects with schizophrenia. PLoS One 2007;2(8):e809
   PubMed Web of Science ®Google Scholar
• Kinoshita M, Numata S, Tajima A, et al. Aberrant DNA methylation of blood in schizophrenia by adjusting for estimated cellular proportions. Neuromolecular Med 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Brucato N, DeLisi LE, Fisher SE, Francks C. Hypomethylation of the paternally inherited LRRTM1 promoter linked to schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2014;165(7):555-63
   Web of Science ®Google Scholar
• Kordi-Tamandani DM, Sahranavard R, Torkamanzehi A. Analysis of association between dopamine receptor genes’ methylation and their expression profile with the risk of schizophrenia. Psychiatr Genet 2013;23(5):183-7
   PubMed Web of Science ®Google Scholar
• Liu J, Chen J, Ehrlich S, et al. Methylation patterns in whole blood correlate with symptoms in schizophrenia patients. Schizophr Bull 2014;40(4):769-76
   PubMed Web of Science ®Google Scholar
• Cheng J, Wang Y, Zhou K, et al. Male-specific association between dopamine receptor D4 gene methylation and schizophrenia. PLoS One 2014;9(2):e89128
   PubMedGoogle Scholar
• Kinoshita M, Numata S, Tajima A, et al. DNA methylation signatures of peripheral leukocytes in schizophrenia. Neuromolecular Med 2013;15(1):95-101
   PubMed Web of Science ®Google Scholar
• Scarr E, Craig JM, Cairns MJ, et al. Decreased cortical muscarinic M1 receptors in schizophrenia are associated with changes in gene promoter methylation, mRNA and gene targeting microRNA. Transl Psychiatry 2013;3:e230
   Web of Science ®Google Scholar
• Kordi-Tamandani DM, Sahranavard R, Torkamanzehi A. DNA methylation and expression profiles of the brain-derived neurotrophic factor (BDNF) and dopamine transporter (DAT1) genes in patients with schizophrenia. Mol Biol Rep 2012;39(12):10889-93
   PubMed Web of Science ®Google Scholar
• Abdolmaleky HM, Nohesara S, Ghadirivasfi M, et al. DNA hypermethylation of serotonin transporter gene promoter in drug naïve patients with schizophrenia. Schizophr Res 2014;152(2-3):373-80
   PubMed Web of Science ®Google Scholar
• Kordi-Tamandani DM, Vaziri S, Dahmardeh N, Torkamanzehi A. Evaluation of polymorphism, hypermethylation and expression pattern of CTLA4 gene in a sample of Iranian patients with schizophrenia. Mol Biol Rep 2013;40(8):5123-8
   PubMed Web of Science ®Google Scholar
• Iwamoto K, Bundo M, Yamada K, et al. DNA methylation status of SOX10 correlates with its downregulation and oligodendrocyte dysfunction in schizophrenia. J Neurosci 2005;25(22):5376-81
   PubMed Web of Science ®Google Scholar
• Zhao C, Wang F, Pun FW, et al. Epigenetic regulation on GABRB2 isoforms expression: developmental variations and disruptions in psychotic disorders. Schizophr Res 2012;134(2-3):260-6
   PubMed Web of Science ®Google Scholar
• Huang HS, Matevossian A, Whittle C, et al. Prefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters. J Neurosci 2007;27(42):11254-62
   PubMed Web of Science ®Google Scholar
• Bromberg A, Levine J, Nemetz B, et al. No association between global leukocyte DNA methylation and homocysteine levels in schizophrenia patients. Schizophr Res 2008;101(1-3):50-7
   PubMed Web of Science ®Google Scholar
• Bönsch D, Wunschel M, Lenz B, et al. Methylation matters? Decreased methylation status of genomic DNA in the blood of schizophrenic twins. Psychiatry Res 2012;198(3):533-7
   PubMed Web of Science ®Google Scholar
• Gavin DP, Kartan S, Chase K, et al. Reduced baseline acetylated histone 3 levels, and a blunted response to HDAC inhibition in lymphocyte cultures from schizophrenia subjects. Schizophr Res 2008;103(1-3):330-2
   PubMed Web of Science ®Google Scholar
• Guidotti A, Auta J, Chen Y, et al. Epigenetic GABAergic targets in schizophrenia and bipolar disorder. Neuropharmacology 2011;60(7-8):1007-16
   PubMed Web of Science ®Google Scholar
• Mahgoub M, Monteggia LM. Epigenetics and psychiatry. Neurotherapeutics 2013;10(4):734-41
   PubMed Web of Science ®Google Scholar
• Boyadjieva N, Varadinova M. Epigenetics of psychoactive drugs. J Pharm Pharmacol 2012;64(10):1349-58
   PubMed Web of Science ®Google Scholar
• Matrisciano F, Tueting P, Dalal I, et al. Epigenetic modifications of GABAergic interneurons are associated with the schizophrenia-like phenotype induced by prenatal stress in mice. Neuropharmacology 2013;68:184-94
   PubMed Web of Science ®Google Scholar
• Li J, Guo Y, Schroeder FA, et al. Dopamine D2-like antagonists induce chromatin remodeling in striatal neurons through cyclic AMP-protein kinase A and NMDA receptor signaling. J Neurochem 2004;90(5):1117-31
   PubMed Web of Science ®Google Scholar
• Kim SH, Lee HY, Yi H, et al. Haloperidol induces demethylation and expression of the dual specificity phosphatase 6 gene in MIA PaCa-2 human pancreatic cancer cells. Life Sci 2012;91(25-26):1317-22
   PubMed Web of Science ®Google Scholar
• Shimabukuro M, Jinno Y, Fuke C, Okazaki Y. Haloperidol treatment induces tissue- and sex-specific changes in DNA methylation: a control study using rats. Behav Brain Funct 2006;2:37
   PubMedGoogle Scholar
• Maćkowiak M, Guzik R, Dudys D, et al. MK-801, a NMDA receptor antagonist, increases phosphorylation of histone H3 in the rat medial prefrontal cortex. Pharmacol Rep 2013;65(5):1112-23
   PubMed Web of Science ®Google Scholar
• Kurita M, Holloway T, García-Bea A, et al. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat Neurosci 2012;15(9):1245-54
   PubMed Web of Science ®Google Scholar
• Aoyama Y, Mouri A, Toriumi K, et al. Clozapine ameliorates epigenetic and behavioral abnormalities induced by phencyclidine through activation of dopamine D1 receptor. Int J Neuropsychopharmacol 2014;17(5):723-37
   PubMed Web of Science ®Google Scholar
• Dong E, Nelson M, Grayson DR, et al. Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. Proc Natl Acad Sci U S A 2008;105(36):13614-19
   PubMed Web of Science ®Google Scholar
• Dong E, Grayson DR, Guidotti A, Costa E. Antipsychotic subtypes can be characterized by differences in their ability to modify GABAergic promoter methylation. Epigenomics 2009;1(1):201-11
   PubMed Web of Science ®Google Scholar
• Yang CP, Wang HA, Tsai TH, et al. Characterization of the neuropsychological phenotype of glycine N-methyltransferase-/- mice and evaluation of its responses to clozapine and sarcosine treatments. ur Neuropsychopharmacol 2012;22(8):596-606
   PubMed Web of Science ®Google Scholar
• Weïwer M, Lewis MC, Wagner FF, Holson EB. Therapeutic potential of isoform selective HDAC inhibitors for the treatment of schizophrenia. Future Med Chem 2013;5(13):1491-508
   PubMed Web of Science ®Google Scholar
• Kundakovic M, Chen Y, Guidotti A, Grayson DR. The reelin and GAD67 promoters are activated by epigenetic drugs that facilitate the disruption of local repressor complexes. Mol Pharmacol 2009;75(2):342-54
   PubMed Web of Science ®Google Scholar
• Kundakovic M, Chen Y, Costa E, Grayson DR. DNA methyltransferase inhibitors coordinately induce expression of the human reelin and glutamic acid decarboxylase 67 genes. Mol Pharmacol 2007;71(3):644-53
   PubMed Web of Science ®Google Scholar
• Sandner G, Host L, Angst MJ, et al. The HDAC inhibitor phenylbutyrate reverses effects of neonatal ventral hippocampal lesion in rats. Front Psychiatry 2011;1:153
   Google Scholar
• Schroeder FA, Lewis MC, Fass DM, et al. A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests. PLoS One 2013;8(8):e71323
   PubMed Web of Science ®Google Scholar
• Sales AJ, Biojone C, Terceti MS, et al. Antidepressant-like effect induced by systemic and intra-hippocampal administration of DNA methylation inhibitors. Br J Pharmacol 2011;164(6):1711-21
   PubMed Web of Science ®Google Scholar
• Sui L, Wang Y, Ju LH, Chen M. Epigenetic regulation of reelin and brain-derived neurotrophic factor genes in long-term potentiation in rat medial prefrontal cortex. Neurobiol Learn Mem 2012;97(4):425-40
   PubMed Web of Science ®Google Scholar
• Schwarz C, Volz A, Li C, Leucht S. Valproate for schizophrenia. Cochrane Database Syst Rev 2008(3):CD004028
   Google Scholar
• Umbricht D, Alberati D, Martin-Facklam M, et al. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. JAMA Psychiatry 2014;71(6):637-46
   PubMed Web of Science ®Google Scholar
• Pinard E, Alanine A, Alberati D, et al. Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia. J Med Chem 2010;53(12):4603-14
   PubMed Web of Science ®Google Scholar
• Grayson DR, Guidotti A. The dynamics of DNA methylation in schizophrenia and related psychiatric disorders. Neuropsychopharmacology 2013;38(1):138-66
   PubMed Web of Science ®Google Scholar
• Penadés R, Pujol N, Catalán R, et al. Brain effects of cognitive remediation therapy in schizophrenia: a structural and functional neuroimaging study. Biol Psychiatry 2013;73(10):1015-23
   PubMed Web of Science ®Google Scholar
• Vinogradov S, Fisher M, Holland C, et al. Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia? Biol Psychiatry 2009;66(6):549-53
   PubMed Web of Science ®Google Scholar